Brain HealthHow Rogue Protein Clumps Drive Alzheimer's and ALS — and How to Stop Them
Many proteins in our cells lack a fixed shape — they are intrinsically disordered — and this flexibility lets them form temporary, liquid-like droplets called biomolecular condensates. These droplets are normal and essential for gene regulation and stress responses. The problem arises when the liquid droplets solidify abnormally. In diseases like Alzheimer's, Parkinson's, ALS, and frontotemporal dementia, key proteins — tau, alpha-synuclein, TDP-43, and FUS — undergo exactly this toxic liquid-to-solid transition, forming aggregates that damage neurons. This comprehensive review synthesizes current understanding of how these transitions happen, what cellular signals control them (including phosphorylation and other chemical modifications), and how new AI-powered tools are accelerating discovery. Critically, it introduces a therapeutic framework called condensate-modifying drugs, proposing four strategies — dissolvers, inducers, localizers, and morphers — to pharmacologically restore normal protein behavior in diseased neurons.
